GlassScriptPhysician profile
Stephen S Bodi
NPI 1548225063
$9,451.25
in general payments reported to CMS, 2019-2025
50 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,330 · 2022: $1,786 · 2023: $2,022 · 2024: $2,038 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,311 · Entertainment: $24.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,310.70 |
| Entertainment | $24.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,135.58 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.23 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $707.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $675.50 | 2021-2025 | |
| Amgen INC. | $656.95 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $631.10 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $487.25 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $433.07 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $379.41 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $310.33 | 2021-2023 | |
| Abbott Laboratories | $291.64 | 2021-2025 | Freestyle Libre 3, Afinion 2, Proclaim |
| Janssen Pharmaceuticals, INC | $281.75 | 2021-2022 | |
| Exact Sciences Corporation | $208.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $207.87 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $184.19 | 2022-2024 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $166.62 | 2022-2025 | Quviviq, Quviviq |
| Antares Pharma, INC. | $143.10 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $142.59 | 2021-2023 | Unithroid |
| Bausch Health US, LLC | $117.37 | 2021-2023 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $116.30 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Kowa Pharmaceuticals America, INC. | $104.16 | 2023-2025 | Zoryve, Seglentis |
| Clarus Therapeutics INC. | $102.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.14 | 2021-2023 | Trintellix |
| Halozyme INC | $87.08 | 2023 | |
| Corium, LLC | $77.44 | 2022-2023 | Azstarys |
| Astellas Pharma US INC | $70.55 | 2021-2024 | Veozah |
| Corcept Therapeutics | $68.94 | 2021-2025 | Korlym |
| Dexcom, INC. | $68.80 | 2024 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $63.51 | 2021 | |
| Esperion Therapeutics, INC. | $63.44 | 2021-2024 | Nexletol |
| Mylan Specialty L.P. | $53.28 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.95 | 2022 | |
| Ibsa Pharma INC. | $47.91 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $47.60 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $46.70 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $41.84 | 2024 | |
| Supernus Pharmaceuticals, INC. | $40.28 | 2021 | Xyosted, Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.31 | 2022 | |
| Axsome Therapeutics, INC. | $35.54 | 2025 | Auvelity |
| Tolmar, INC. | $31.97 | 2023 | |
| Sanofi-Aventis U.S. LLC | $31.90 | 2021-2022 | |
| Allergan, INC. | $29.99 | 2021 | |
| Biogen, INC. | $26.57 | 2024 | Leqembi |
| Optos, INC. | $24.52 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tms Neurohealth Centers INC. | $19.57 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $18.81 | 2025 | Jornay Pm |
| Vbi Vaccine (Delaware) INC. | $17.07 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.94 | 2025 | Nuzyra |
| Currax Pharmaceuticals LLC | $16.84 | 2023 | Contrave |
| Medicure Pharma INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.